Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, and Pieris Pharmaceuticals, Inc. (Nasdaq: PIRS) (Pieris) announce they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on developing and commercializing Palvella’s lead clinical product candidate, QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin).
Read the full article: Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement //
Source: https://www.pieris.com/investors/news-events/press-releases/detail/707/palvella-therapeutics-and-pieris-pharmaceuticals-announce